RxDoctor Payments Data

Teresa Fotino, PA

Physician Assistant · New Windsor, NYNPI 1376177436

Payments from drug & device makers

$2,793in general payments, 2019–2025

Across 141 payments — averaging $19.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$702
  • Antares Pharma, Inc.$581
  • Sumitomo Pharma America, Inc.$297
  • Coloplast$282
  • Boston Scientific$115
  • Halozyme Inc$107
  • plus $709 from 19 others

What the payments were for

  • Food & beverage$2,793100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,793 in reported general payments places this provider in the 85th percentile of 11,358 physician assistant providers in New York.

See all physician assistant providers in New York

Medicare billing

Part B allowed, 2024
$54,590
Medicare patients
294
Services billed
1,170

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron43$40,199
MyrbetriqMirabegron53$37,312
Tamsulosin Hcl256$3,620
Estradiol38$3,068
Silodosin24$1,734
NitrofurantoinNitrofurantoin Macrocrystal43$1,490
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst81$1,387
Oxybutynin Chloride ErOxybutynin Chloride41$915
Tolterodine Tartrate ErTolterodine Tartrate17$787
Finasteride52$549
Alfuzosin Hcl ErAlfuzosin Hcl21$529
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav67$433
Ciprofloxacin Hcl68$296
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim45$168
Levofloxacin35$113

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$297$40,19943 claims
Astellas Pharma US IncMyrbetriq$97$37,31253 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 11,358 physician assistant providers in New York.

Other physician assistant in New Windsor

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →